Letter: intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitors
Open Access
- 3 June 2020
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (3), 569-570
- https://doi.org/10.1111/apt.15814
Abstract
We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID‐19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID‐19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID‐19.[2]Keywords
Funding Information
- Broad Medical Research Program (IBD-0360)
This publication has 11 references indexed in Scilit:
- Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19New England Journal of Medicine, 2020
- Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19New England Journal of Medicine, 2020
- 2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseasesAlimentary Pharmacology & Therapeutics, 2020
- Evidence for Gastrointestinal Infection of SARS-CoV-2Gastroenterology, 2020
- Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Gut, 2020
- Faecal calprotectin indicates intestinal inflammation in COVID-19Gut, 2020
- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic targetIntensive Care Medicine, 2020
- Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodellingEP Europace, 2016
- Age- and gender-related difference of ACE2 expression in rat lungLife Sciences, 2006